Overview

Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This is a pilot study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to pembrolizumab.

Phase:

Early Phase 1

Details

Lead Sponsor:

Laura Esserman

Collaborators:

Merck Sharp & Dohme Corp.
ModernaTX, Inc.

Treatments:

Pembrolizumab